Valuation : Impax Laboratories Inc

Market Cap 6.07B 5.23B 4.91B 4.49B 8.4B 574B 8.43B 58.1B 22.52B 294B 22.81B 22.31B 949B P/E 2026 *
38.8x
P/E 2027 * 19.7x
Enterprise Value 8.39B 7.23B 6.79B 6.21B 11.61B 793B 11.65B 80.26B 31.12B 406B 31.51B 30.82B 1,311B EV / Sales 2026 *
2.66x
EV / Sales 2027 * 2.35x
Free-Float
44.34%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 2019-07-31
Chief Executive Officer 54 2019-07-31
Director of Finance/CFO 58 2023-11-06
Director TitleAgeSince
Director/Board Member 59 2023-11-06
Director/Board Member 70 2023-11-06
Director/Board Member 52 2023-11-06
Change 5-day change 1-year change 3-year change Capi.($)
-2.00%-2.92% - - 6.07B
-0.88%-2.15%+54.71%+106.31% 1,024B
-1.15%+2.68%+53.97%+71.50% 663B
-1.44%+0.38%+20.40%+73.05% 453B
+0.14%-0.47%+29.49%+38.56% 352B
-1.33%+4.72%+24.69%+45.55% 304B
-1.15%+0.30%-1.49%+12.31% 252B
-1.55%+1.11%+56.10%+70.32% 236B
-0.88%+1.15%-17.09%-54.39% 206B
-0.15%+3.65%+33.90%+96.99% 187B
Average -1.04%+1.09%+28.30%+51.13% 408.71B
Weighted average by Cap. -0.96%+0.55%+36.62%+66.22%

Financials

2026 *2027 *
Net sales 3.15B 2.72B 2.55B 2.33B 4.36B 298B 4.38B 30.17B 11.69B 153B 11.84B 11.58B 493B 3.43B 2.95B 2.77B 2.54B 4.75B 324B 4.76B 32.81B 12.72B 166B 12.88B 12.6B 536B
Net income 149M 128M 120M 110M 206M 14.06B 207M 1.42B 552M 7.21B 559M 547M 23.25B 295M 254M 238M 218M 408M 27.85B 409M 2.82B 1.09B 14.27B 1.11B 1.08B 46.05B
Net Debt 2.32B 2B 1.88B 1.71B 3.21B 219B 3.22B 22.17B 8.59B 112B 8.7B 8.51B 362B 2B 1.72B 1.61B 1.48B 2.76B 189B 2.77B 19.08B 7.4B 96.62B 7.49B 7.33B 312B
Logo Impax Laboratories Inc
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
Employees
-
Trader
Investor
Global
Quality
-
ESG MSCI
-